Advertisement

Phentolamine Infusion Therapy

  • Michael J. Suer
  • Alaa Abd-Elsayed
Chapter

Abstract

Phentolamine (phentolamine mesylate), a non-selective alpha-adrenergic receptor antagonist, has traditionally been used in hypertensive crises due to pheochromocytoma, extravasation management, and local anesthesia reversal. But recent research has also suggested applications beyond these indications including uses for abdominal cancer pain and neuropathic pain.

Keywords

Phentolamine Infusion Pain Sympathetic mediated pain Abdominal visceral cancer 

References

  1. 1.
    Product information: phentolamine mesylate injection, phentolamine mesylate injection. Bedford Laboratories, Bedford, 1999.Google Scholar
  2. 2.
    Product information: Phentolamine mesylate IM, IV injection Sandoz Standard, phentolamine mesylate IM, IV injection Sandoz Standard. Sandoz Canada (per manufacturer), Boucherville, 2005.Google Scholar
  3. 3.
    Tuncel M, Ram VC. Hypertensive emergencies. Etiology and management. Am J Cardiovasc Drugs. 2003;3(1):21–31.CrossRefGoogle Scholar
  4. 4.
    Mark PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131:1949–62.CrossRefGoogle Scholar
  5. 5.
    Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134(4):315–29.CrossRefGoogle Scholar
  6. 6.
    Shenfield O, Hanani J, Shalhav A, et al. Papaverine-phentolamine and prostaglandin E1versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol. 1995;154(3):1017–9.CrossRefGoogle Scholar
  7. 7.
    Product information: ORA VERSE (TM) submucosal injection, phentolamine mesylate submucosal injection. Novalar Pharmaceuticals, Inc., San Diego, 2008.Google Scholar
  8. 8.
    Goldstein I, Carson C, Rosen R, et al. Vasomax for the treatment of male erectile dysfunction. World J Urol. 2001;19:51–6.CrossRefGoogle Scholar
  9. 9.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.CrossRefGoogle Scholar
  10. 10.
    Bussa M, Guttilla D, Lucia M, et al. Complex regional pain syndrome type I: a comprehensive review. Acta Anaesthesiol Scand. 2015;59:685–97.CrossRefGoogle Scholar
  11. 11.
    Uçeyler N, Eberle T, Rolke R, et al. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. 2007;132(1–2):195–205.CrossRefGoogle Scholar
  12. 12.
    Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010;113(3):713–25.PubMedGoogle Scholar
  13. 13.
    Lavand’homme PM, Ma W, De Kock M, Eisenach JC. Perineural alpha (2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology. 2002;97:972–80.CrossRefGoogle Scholar
  14. 14.
    Drummond PD, Skipworth S, Finch PM. Alpha 1-adrenoreceptors in normal and hyperalgesic human skin. Clin Sci (Lond). 1996;91:73–7.CrossRefGoogle Scholar
  15. 15.
    Raja SN, Davis KD, Campbell JC. The adrenergic pharmacology of sympathetically-maintained pain. J Reconstr Microsurg. 1992;8:63–9.CrossRefGoogle Scholar
  16. 16.
    Devor M, Janig W, Michaelis M. Modulation of activity in dorsal root ganglion neurons by sympathetic activation in nerve-injured rats. J Neurophysiol. 1994;71:38–47.CrossRefGoogle Scholar
  17. 17.
    Dellemijn PL, Fields HL, Allen RR, et al. The interpretation of pain relief and sensory changes following sympathetic blockade. Brain. 1994;117:1475–87.CrossRefGoogle Scholar
  18. 18.
    Wehnert Y, Muller B, Larsen B, et al. Sympathetically maintained pain (SMP): phentolamine versus sympathetic nerve blockade. Comparison of two diagnosic methods. Orthopade. 2002;31:1076–83.CrossRefGoogle Scholar
  19. 19.
    Arner S. Intravenous phentolamine test: diagnostic and prognostic use in reflex sympathetic dystrophy. Pain. 1991;46:17–22.CrossRefGoogle Scholar
  20. 20.
    Moriwaki K, Yuge O, Shimada S, Collins JG. Phentolamine IV causes reduction in the size of receptive fields of low threshold spinal neurons. Anesth Resuscit. 2008;44:31–5.Google Scholar
  21. 21.
    Ogon I, Takebayashi T, Miyakawa T, et al. Suppression of sympathetic nerve sprouting by local administration of an alpha-agonist around the dorsal root ganglion in a lumbar radiculopathy model. Spine. 2018;43:E321–6.PubMedGoogle Scholar
  22. 22.
    Davis KD, Treede RD, Raja SN, et al. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain. 1991;47:309–17.CrossRefGoogle Scholar
  23. 23.
    Byas-Smith MG, Max MB, Muir J, Klingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage enriched enrollment design. Pain. 1995;60:267–74.CrossRefGoogle Scholar
  24. 24.
    Park CH, Yong A, Ho Lee S. Involvement of selective alpha-2 adrenoreceptor in sympathetically maintained pain. J Korean Neurosurg Soc. 2010;47:420–3.CrossRefGoogle Scholar
  25. 25.
    WHO analgesic pain ladder available online. www.who.int/cancer/palliative/painladder/en/. Accessed 21 Dec 2018.
  26. 26.
    McCleane GJ. Intravenous phentolamine mesylate alleviates the pain of pancreatic carcinoma. Pain. 1997;73:263–4.CrossRefGoogle Scholar
  27. 27.
    Yasukawa M, Yasuakwa K, Kamizumi Y, Yokoyama R. Intravenous phentolamine infusion alleviates the pain of abdominal visceral cancer, including pancreatic carcinoma. J Anesth. 2007;21:420–3.CrossRefGoogle Scholar
  28. 28.
    McCleane GJ. Phentolamine abolishes the pain of chronic pancreatitis. Br J Hosp Med. 1996;55:521–2.PubMedGoogle Scholar
  29. 29.
    McCleane GJ. Phentolamine mesylate can alleviate the visceral pain associated with acute intermittent porphyria. Pain Clin. 1997;10:130–2.Google Scholar
  30. 30.
    McCleane GJ. Phentolamine mesylate can alleviate the nausea and vomiting associated with liver metastases. Ulster Med J. 1996;65:165–6.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Hoffman BB, Michel T, Kilpatrick DM, et al. Agonist versus antagonist binding to alpha-adrenergic receptors. Proc Natl Acad Sci U S A. 1980;77(8):4569–73.CrossRefGoogle Scholar
  32. 32.
    Kearney TE. Phentolamine. In: Olson K, editor. Poisoning & drug overdose. 7th ed. McGraw-Hill; 2018. p. 605–6. Print.Google Scholar
  33. 33.
    Phentolamine: Drug Information. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/phentolamine-drug-information. Accessed 4 Dec 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michael J. Suer
    • 1
  • Alaa Abd-Elsayed
    • 2
  1. 1.Physical Medicine and RehabilitationUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  2. 2.Department of AnesthesiologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations